Denosumab + Zoledronic Acid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bone Metastases
Conditions
Bone Metastases
Trial Timeline
Apr 1, 2006 → Apr 4, 2012
NCT ID
NCT00321464About Denosumab + Zoledronic Acid
Denosumab + Zoledronic Acid is a phase 3 stage product being developed by Daiichi Sankyo for Bone Metastases. The current trial status is completed. This product is registered under clinical trial identifier NCT00321464. Target conditions include Bone Metastases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00321464 | Phase 3 | Completed |
Competing Products
20 competing products in Bone Metastases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Merestinib | Eli Lilly | Phase 1 | 33 |
| FORTEO + Placebo | Eli Lilly | Phase 1 | 33 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 77 |
| Tanezumab | Eli Lilly | Phase 3 | 77 |
| Anastrozole + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 1 | 33 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 77 |
| zoledronic acid | Novartis | Phase 1 | 33 |
| Ruxolitinib continuous therapy | Novartis | Phase 2 | 52 |
| zoledronic acid | Novartis | Approved | 85 |